Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare
The April 28, 2021 Early Release of this week’s MMWR (CDC’s Morbidity and Mortality Weekly Report) provides this very encouraging information!
“In the current report, Pfizer-BioNTech and Moderna vaccine products were equally represented, and approximately one half of the patients were aged ≥75 years, providing evidence of real-world effectiveness of both vaccines against an important measure of severe COVID-19 in older adults. Moreover, in assessing the impact of receiving only a single dose, no significant vaccine effectiveness <14 days after the first dose of a SARS-CoV-2 vaccine was detected. This suggests that bias is unlikely in the primary estimates of vaccine effectiveness from partial and full vaccination. This also highlights the continued risk for severe illness shortly after vaccination, before a protective immune response has been achieved and reinforces the need for vaccinated adults to continue physical distancing and prevention behaviors, such as use of face masks and recommended hand hygiene at least 14 days after the second dose of a 2-dose vaccine. The findings suggest that SARS-CoV-2 vaccines can reduce the risk for COVID-19–associated hospitalization and, as a consequence of preventing severe COVID-19, vaccination might have an impact on post-COVID conditions (e.g., “long COVID”) and deaths.” (Bolding added by me.)
Check out the table on page 4 of the PDF version – Characteristics of adults aged ≥65 years with COVID-19–like illness tested for SARS-CoV-2 infection, by COVID-19 case status — 24 medical centers in 14 states, January–March 2021.